Increasing evidence has been reported for the synergistic and additive effects of the joint use of HDAC inhibitors and BRAF inhibitors in colon cancer and melanoma (Lai et al., 2013; Carson et al., 2015; Fu et al., 2019). This evidence concerns the gene BRAF and melanoma.